

No.F.4/1/2023-PPD(pt.)  
Government of India  
Ministry of Finance  
Department of Expenditure  
Procurement Policy Division  
\*\*\*\*\*

515, Lok Nayak Bhavan,  
Khan Market, New Delhi,  
09.08.2024

**OFFICE MEMORANDUM**

**Subject: Relaxation under Rule 161(iv) of General Financial Rules 2017 for issuance of Global Tender Enquiry (GTE) for procurement of Drugs.**

Attention is invited to this Department's OM No. F.12/17/2019-PPD dated 15.05.2020 regarding amendment in Rule 161(iv) of General Financial Rules (GFRs) 2017 stipulating that no Global Tender Enquiry (GTE) shall be invited for tenders upto Rs.200 crore. However, in exceptional cases, where the Ministry or the Department feels that there are special reasons for issuance of GTE, it may record its detailed justification and seek prior approval for relaxation to the above Rule from the competent authority i.e. Secretary (Coordination), Cabinet Secretariat.

2. In above context, on the recommendation of Ministry of Health and Family Welfare (MoH&FW), 120 drugs were exempted, vide this Department's OM No. 4/1/2023-PPD (pt.) dated 07.06.2024, from the instructions issued by this Department OMs No. 12/17/2019-PPD dated 15.05.2020 & 28.05.2020 till 31.03.2027 or further orders.

3. MoH&FW (efile No. 102-1/2023-24/CGHS/MSD) has now requested to exempt 07 more drugs from the above said instructions dated 15.05.2020 & 28.05.2020 regarding GTEs. As requested by MoH&FW, exemptions will now be available for 127 drugs listed at Annexure A till 31.03.2027 or further orders.

**Encls: As above.**



(Sher Bahadur)  
Under Secretary (Procurement Policy)  
Tel.: 24653771  
Email: [sher.bahadur@nic.in](mailto:sher.bahadur@nic.in)

To,

All the Secretaries and Financial Advisors to Government of India.

Copy to:

Secretary (Coordination), Cabinet Secretariat, Rashtrapati Bhawan, New Delhi.

Annexure - A

S.No	Name of the Drug
1	Abemaciclib 50mg/100mg/150mg/200mg
2	Abrocitinib Tab 50 mg/100mg/ 200 mg
3	AFLIBERCEPT 40 MG
4	ALECENSA 150 MG [(Alectinib (150mg)]
5	Alglucosidase Alfa vial for Inj.
6	Amivantamab 350 mg
7	ATEZOLIZUMAB 840 MG/ 1.2MG
8	Avalglucosidase Alfa-ngpt vial for inj.
9	Avelumab injection: 200 mg/10 mL (20 mg/mL) solution in single-dose vial
10	BASILIXIMAB 20 MG
11	Brolucizumab solution for injection 120 mg/ml(vial + filter needle)
12	Capmatinib Film-coated Tablet 200 mg
13	Catridecacog (rDNA factor XIII 2500IU)
14	Crizanlizumab 100mg/ 10ml
15	Crizotinib Tab/Capsule (250 Mg)
16	Dabrafenib capsules 75 mg
17	DARATUMUMAB 100 MG 400mg & Daratumumab Subcutaneous(Faspro) 1800 mg
18	DEGLUDEC 100 I.U./ML INSULIN. PREFILLED PEN 3 ML.
19	Desflurane Anaesthetic Liquid (SUPRANE)
20	Detemir Insulin 100 IU/ml 3ml Pen
21	Dulaglutide 0.75 MG (BRAND TRULICITY 0.75MG pre filled pen) & Dulaglutide Inj- (Brand TRULICITY 1.5mg Pre Filled Pen
22	Dupilumab Injection 300mg/2ml and 200mg/1.14ml
23	DURVALUMAB 120 MG/ 500MG
24	EMPAGLIFLOZIN + METFORMIN TABS VARIOUS FIXED DOSE COMBINATION)
25	Evrysdi 0.75MG/1ML 80 POSO IN (Risdiplam)
26	Fabrazyme (Agalsidase beta)

*AB*



27	FACTOR EIGHT INHIBITOR BYPASSING ACTIVITY - Containing : Factor Eight Bypassing activity, Anti-Inhibitor-Congulant Complex. 500 IU.
28	FASENRA™ (Benralizumab, prefilled syringe) Benralizumab Each injection contains Benralizumab 30mg
29	FINERENONE 10 MG / 20 mg TAB
30	Genryzon (SomatogroPn)
31	Golimimumab 50mg/0.5ml [Simponi 50mg Injection-J&J]
32	Herpes Zoster Vaccine recombinant adjuvanted Brand Name: Shingrix
33	HUMAN COAGULATION FACTOR VII INJ - Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 1 mg Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 2mg
34	Idursulfase injection : 6 mg/3 ml, (2 mg/mL) in single-use vial
35	Imiglucerase injection: 400 units of imiglucerase as a lyophilized powder in a single-dose vial.
36	Inj Natalizumab 300mg/15ml
37	INJ PANITUMUMAB 100 MG
38	INJ PEMBROLIZUMAB 100 MG
39	Inj Spesolimab IV infusion 450 mg/7.5ml
40	Inj Tissue type plasminogen activator (tPA)
41	Inj. Insulin Degludec 70% + Insulin Aspart 30% 100 IU/ml., 3 ml. Cartridge (RYZODEG PENFILL.)
42	Inj. Ixekizumab 80mg (Copellor)
43	INJ. MEPOLIZUMAB SOLUTION 100 MG
44	Inj. Thyrotropin alfa 1.1 mg (THYROGEN)
45	Inonza (Inotuzumab Ozogamicin)
46	Insulin Analogue of 50% Insulin Aspart + 50% longer acting analogue 100 IU/ml.
47	Insulin Aspart Inj- Each Vial to contain: Insulin Aspart (r-DNA Origin)
48	INSULIN GLULISINE INJECTION(MONOCOMPONENT INSULIN GLULISINE) 100 I.U./ML.3ML

*AB*



49	Insulin Inj-Each Cartridge to contain: 25% Lispro And 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin] & 3ml Cartridge. Each Cartridge to contain: 50% Lispro And 50% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin] & 3ml Cartridge
50	Intravitreal Dexamethasone Implant- Each inj to contain: Intravitreal Dexamethasone 0.7mg
51	KADCYLA (Trastuzumab emtansine) (Sterile powder for concentrate for infusion solution 100mg and 160mg vial [20mg/ml])
52	Kyzific® (Asciminib film-coated tablets 40 mg)
53	Laronidase injection: 2.9 mg/5 mL (0.58 mg/mL) of Laronidase in a single-dose vial
54	Lemtrada (Alemtuzumab)
55	Lorbriqua® (Lorlatinib)
56	Luspatercept 25 mg and 75 mg [Brand Name: Rojuzda]
57	Lutropin Alfa-r-DNA (Recombinant Leutinising Hormone 75 IU) Powder with 1ml solvent for solution for injection
58	Miglustat (Zavesca) (Opfolda)
59	Obinutuzumab Inj- Each Vial to contain: Obinutuzumab 1000 mg
60	OCREVUS ( Ocrelizumab)Concentrate for solution for infusion 300 mg/10 mL vial [30 mg/mL]
61	Olipudase alfa-rpcp vial for Inj.
62	Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml)
63	PHESGO Solution for subcutaneous injection 600mg + 600 mg (10 ml/15cc vial) 1200mg + 600mg (15ml/20cc vial) Pertuzumab (600mg) + Trastuzumab (600mg) Pertuzumab (1200mg) + Trastuzumab (600mg)
64	Pneumovax 23(pneumococcal vaccine polyvalent for 23 serotypes) & Pneumococcal Vaccine- Each 0.5ml to contain: Pneumococcal Polysaccharide Conjugate Vaccine (13 Valent)

*AS*